Skip to main content Accessibility help
×
Home
  • Print publication year: 2014
  • Online publication date: August 2014

Chapter 5 - Antiepileptic drugs and hormones

References

1. Herzog AG, Seibel MM, Schomer DL, et al. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986; 43:341–6.
2. Isojärvi JI. Reproductive dysfunction in women with epilepsy. Neurology 2003; 61(6 Suppl 2):S27–S34.
3. Cummings LN, Giudice L and Morrell MJ. Ovulatory function in epilepsy. Epilepsia 1995; 36:355–60.
4. Dansky LV, Andermann E and Andermann F. Marriage and fertility in epileptic patients. Epilepsia 1980; 21:261–71.
5. Wallace H, Shorvon S and Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet 1998; 352:1970–73.
6. Artama M, Isojärvi JI, Raitanen J, et al. Birth rate among patients with epilepsy: a nationwide population-based cohort study in Finland. Am J Epidemiol 2004; 159:1057–63.
7. Sukumaran SC, Sarma PS and Thomas SV. Polytherapy increases the risk of infertility in women with epilepsy. Neurology 2010; 75(15):1351–5.
8. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, et al. Menstrual disorders in women with epilepsy receiving carbamazepine. Epilepsia 1995; 36:676–81.
9. Isojarvi JIT, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. New Engl J Med 1993; 329(19):1383–9.
10. Isojärvi JI, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43:446–51.
11. Mikkonen K, Vainionpää LK, Pakarinen AJ, et al. Long-term reproductive endocrine health in young women with epilepsy during puberty. Neurology 2004; 62:445–50.
12. Isojarvi J. Disorders of reproduction in patients with epilepsy: antiepileptic drug related mechanisms. Seizure 2008; 17:111–19.
13. Verrotti A, D’Egidio C, Mohn A, et al. Antiepileptic drugs, sex hormones, and PCOS. Epilepsia 2011; 52:199–211.
14. Bauer J, Jarre A, Klingmuller D, et al. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 2000; 41:163–7.
15. Bentley-Lewis R, Ellen Seely E and Dunaif A. Ovarian hypertension: polycystic ovary syndrome. Endocrinol Metab Clin North Am 2011; 40:433–8.
16. Herzog AG, Coleman AE, Jacobs AR, at al. Interictal EEG discharges, reproductive hormones, and menstrual disorders in epilepsy. Ann Neurol 2003; 54:625–37.
17. Herzog AG. Disorders of reproduction in patients with epilepsy: primary neurological mechanisms. Seizure 2008; 17:101–10.
18. Rasgon NL, Altshuler LL, Fairbanks L, at al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005; 7:246–59.
19. Sahota P, Prabhakar S, Kharbanda PS, at al. Seizure type, antiepileptic drugs, and reproductive endocrine dysfunction in Indian women with epilepsy: a cross-sectional study. Epilepsia 2008; 49:2069–77.
20. Morrell MJ, Hayes FJ, Sluss PM, at al. Hyperandrogenism, ovulatory dysfunction, polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol 2008; 64:200–11.
21. Speroff L, Glass RH and Kase NG. Clinical gynecologic endocrinology and infertility. 7th edn. Philadelphia, IL: Lippincott Williams & Wilkins, 2004.
22. Taubøll E, Gregoraszczuk EL, Kołodziej A, at al. Valproate inhibits the conversion of testosterone to estradiol and acts as an apoptotic agent in growing porcine ovarian follicular cells. Epilepsia 2003; 44:1014–21.
23. Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, at al. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 2004; 145:799–808.
24. Svalheim S, Taubøll E, Luef G, at al. Differential effects of levetiracetam, carbamazepine, and lamotrigine on reproductive endocrine function in adults. Epilepsy Behav 2009; 16:281–7.
25. Margraf JW and Dreifuss FE. Amenorrhea following initiation of therapy with valproic acid. Neurology 1981; 31(Suppl):S159.
26. Klein P, Serje A and Pezzullo JC. Premature ovarian failure in women with epilepsy. Epilepsia 2001; 42:1584–9.
27. Morrell MJ and Guldner GT. Self-reported sexual function and sexual arousability in women with epilepsy. Epilepsia 1996; 37:1204–10.
28. Morrell MJ, Flynn KL, DoÇe S, et al. Sexual dysfunction, sex steroid hormone abnormalities, and depression in women with epilepsy treated with antiepileptic drugs. Epilepsy Behav 2005; 6:360–5.
29. Herzog AG, Coleman AE, Jacobs AR, at al. Relationship of sexual dysfunction to epilepsy laterality and reproductive hormone levels in women. Epilepsy Behav 2003; 4:407–13.
30. Morrell MJ, Flynn KL, Seale CG, at al. Reproductive dysfunction in women with epilepsy: antiepileptic drug effects on sex-steroid hormones. CNS Spectr 2001; 6:783–6.
31. Galimberti CA, Magri F, Copello F, at al. Changes in sex steroid levels in women with epilepsy on treatment: relationship with antiepileptic therapies and seizure frequency. Epilepsia 2009; 50:(Suppl 1):28–32.
32. Lossius MI, Taubøll E, Mowinckel P, et al. Reversible effects of antiepileptic drugs on reproductive endocrine function in men and women with epilepsy – a prospective randomized double-blind withdrawal study. Epilepsia 2007; 48:1875–82.
33. Harden CL. Sexuality in women with epilepsy. Epilepsy Behav 2005; 7(Suppl 2):S2–S6.
34. Ben-Menachem E. Weight issues for people with epilepsy – a review. Epilepsia 2007; 48(Suppl 9):42–5.
35. Verrotti A, D’Egidio C, Mohn A, at al. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev 2011; 12:e32–43.
36. El-Khatib F, Rauchenzauner M, Lechleitner M, et al. Valproate, weight gain and carbohydrate craving: a gender study. Seizure 2007; 16:226–32.
37. Abaci A, Saygi M and Yis U. Metabolic alterations during valproic acid treatment: a prospective study. Pediatr Neurol 2009; 41:435–9
38. Tokgoz H, Aydin K, Oran B, et al. Plasma leptin, neuropeptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproate. Childs Nerv Syst 2012; 28:1049–53.
39. Chang HH, Yang YK, Gean PW, et al. The role of valproate in metabolic disturbances in bipolar disorder patients. J Affect Disord 2010; 124:319–23.
40. Verrotti A, Manco R, Agostinelli S, et al. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia 2010; 51:268–73.
41. Laghate VD and Gupta SB. Acute pancreatitis and diabetic ketoacidosis in non-diabetic person while on treatment with sodium valproate, chlorpromazine and haloperidol. J Assoc Physicians India 2004; 52:257–8.
42. Saito E and Kafantaris V. Can diabetes mellitus be induced by medication? J Child Adolesc Psychopharmacol 2002; 12:231–6.
43. Pylvänen V, Knip M, Pakarinen A, et al. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002; 43:514–7.
44. Pylvänen V, Pakarinen A, Knip M, et al. Characterization of insulin secretion in valproate-treated patients with epilepsy. Epilepsia 2006; 47:1460–4.
45. Steinhoff BJ. Optimizing therapy of seizures in patients with endocrine disorders. Neurology 2006; 67(Suppl 4):S23–S7.
46. Cabrera J, Emir B, Dills D, et al. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin 2012; 28:1027–37.
47. Uthman BM, Bazil CW, Beydoun A, et al. Long-term add-on pregabalin treatment in patients with partial-onset epilepsy: pooled analysis of open-label clinical trials. Epilepsia 2010; 51:968–78.
48. Guberman A and Bruni J. Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group. Seizure 2000; 9:112–8.
49. Ben-Menachem E, Axelsen M, Johanson EH, et al. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003; 11:556–62
50. Arroyo S, Dodson WE, Privitera MD, et al. Investigators randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 2005; 112:214–22.
51. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012; 20:330–42.
52. Caricilli AM, Penteado E, de Abreu LL, et al. Topiramate treatment improves hypothalamic insulin and leptin signaling and action and reduces obesity in mice. Endocrinology 2012; 153:4401–11.
53. Khanna V, Arumugam S, Roy S, et al. Topiramate and type 2 diabetes: an old wine in a new bottle. Expert Opin Ther Targets 2008; 12:81–90.
54. Shafik AN. Effects of topiramate on diabetes mellitus induced by streptozotocin in rats. Eur J Pharmacol 2012; 684:161–7.
55. Stenlöf K, Rössner S, Vercruysse F, et al. OBDM-OBDM-003 Study Group. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab 2007; 9:360–8.
56. Rosenstock J, Hollander P, Gadde KM, et al. OBD-202 Study Group. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care 2007; 30:1480–6.
57. Faught E, Ayala R, Montouris GG, et al. Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001; 57:1774–9.
58. Gadde KM, Kopping MF, Wagner HR, et al. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med 2012; 15:1–8.
59. Pennell PB. Hormonal aspects of epilepsy. Neurol Clin 2009; 27:941–65.
60. Vainionpää LK, Mikkonen K, Rättyä J, et al. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication. Epilepsia 2004; 45:197–203.
61. Verrotti A, Laus M, Scardapane A, et al. Thyroid hormones in children with epilepsy during long-term administration of carbamazepine and valproate. Eur J Endocrinol 2009; 160:81–6.
62. Dong X, Leppik IE, White J, et al. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005; 27:1976–8.
63. Lin CH, Lu CH, Wang FJ, et al. Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy. Clin Neuropharmacol 2010; 33:293–6.
64. Isojärvi JI, Huuskonen UE, Pakarinen AJ, et al. The regulation of serum sodium after replacing carbamazepine with oxcarbazepine. Epilepsia 2001; 42:741–5.
65. Beers E, van Puijenbroek EP, Bartelink IH, et al. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatraemia associated with valproic acid: four case reports from the Netherlands and a case/non-case analysis of vigibase. Drug Saf 2010; 33:47–55.
66. Nasrallah K and Silver B. Hyponatremia associated with repeated use of levetiracetam. Epilepsia 2005; 46:972–3.